EINSTEIN-PE (2012)

Traditional anticoagulation for pulmonary embolism (PE) with heparin followed by vitamin K antagonists (VKAs) is effective but has limitations, including the need for parenteral administration and frequent monitoring. The EINSTEIN-PE trial aimed to evaluate if a single oral anticoagulant, rivaroxaban, could be a safe and effective alternative for the treatment of acute symptomatic PE.

This was an open-label, randomized, non-inferiority trial comparing rivaroxaban (15 mg twice daily for 3 weeks, then 20 mg once daily) with enoxaparin followed by a VKA for 3, 6, or 12 months in patients with acute symptomatic PE. The primary efficacy outcome was recurrent venous thromboembolism (VTE), and the principal safety outcome was major bleeding.

Rivaroxaban was non-inferior to conventional therapy for the primary efficacy outcome of recurrent VTE (2.1% in the rivaroxaban group vs. 1.8% in the standard-therapy group; HR 1.12; 95% CI 0.75-1.68; P=0.003 for non-inferiority). The principal safety outcome of major bleeding occurred at similar rates (1.1% with rivaroxaban vs. 2.2% with standard therapy; HR 0.49; 95% CI 0.31-0.79; P=0.003 for superiority). This suggests rivaroxaban was at least as effective and potentially safer regarding major bleeding.

Rivaroxaban is a safe and effective single-drug oral anticoagulant for the treatment of acute symptomatic PE, offering a convenient alternative to traditional VKA therapy without the need for initial parenteral anticoagulation.

The trial was open-label, which could introduce bias, especially for subjective outcomes. Patients with massive PE requiring thrombolysis or embolectomy were excluded, limiting generalizability to the sickest PE patients.